GOG

Guild of Guardians Set to Revolutionize Mobile Gaming with Official Global Release on May 15

Retrieved on: 
Thursday, March 21, 2024
Bandai Namco Holdings, SK Gaming, RPG, Team Liquid, Altar, Cloud9, Trailer, The Last of Us, NRG, Google Play, NFT, Golden Joystick Awards, Non-fungible token, App Store (iOS/iPadOS), Game, GOG, Polygon, Ecosystem, Final Fantasy, Dread, The Altar, Riot Games, AAA, Square Enix, Video game

SYDNEY, March 21, 2024 /PRNewswire/ -- Immutable Games today announced the official launch date of its flagship title, Guild of Guardians (GOG), a highly anticipated mobile squad-based RPG with over 1 million pre-registered users. Developed with the highly acclaimed studio, Mineloader, known for co-developing and working on some of the world's biggest AAA titles such as The Division 2, The Last of Us Part I, and the Final Fantasy series, GOG is set to make its global debut on May 15. Starting May 15, players worldwide can dive into the fantastical world of Elderym, building their ultimate team of Guardians to conquer the Dread. The game will be available on the Google Play and Apple App Store, following a highly successful soft launch in Canada, Australia and Indonesia where it gained an impressive 4.9 rating on the App Store.

Key Points: 
  • SYDNEY, March 21, 2024 /PRNewswire/ -- Immutable Games today announced the official launch date of its flagship title, Guild of Guardians (GOG), a highly anticipated mobile squad-based RPG with over 1 million pre-registered users.
  • Starting May 15, players worldwide can dive into the fantastical world of Elderym, building their ultimate team of Guardians to conquer the Dread.
  • With more than 1 million pre-registered users, and a passionate global community of over 400,000, Guild of Guardians is poised for global success.
  • Launching on mobile allows us to bridge the gap between traditional gaming and the emerging world of blockchain gaming," said Chris Clay, Game Director for Guild of Guardians.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Retrieved on: 
Friday, January 12, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Histopathology, Weight loss, Gynaecology, Bevacizumab, Cisplatin, Hypothyroidism, University, Cancer, Risk, COVID-19, Diarrhea, Hyperthyroidism, Brachytherapy, Neoplasm, Perforated ulcer, Hepatitis, FIGO, CRT, Pyelonephritis, Colitis, Vagina, ClinicalTrials.gov, PD-L1, RECIST, Disease, Patient, Fever, CPS, Chemoradiotherapy, Vomiting, MRK, Death, Nephritis, Progression-free survival, OS, Radiation, Anemia, Survival, EBRT, Abdominal pain, Intraparenchymal hemorrhage, Uterus, Cervical cancer, Constipation, PFS, Fatal, Obstetrics, Hematopoietic stem cell transplantation, Pneumonitis, Nausea, Pelvic pain, Dysuria, Fatigue, GOG, Arm, Rash, Food, Merck & Co., Sepsis, Toxicity, News, Urinary tract infection, Appetite, Pharmaceutical industry

Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Key Points: 
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • “Building on the established role of KEYTRUDA in advanced cervical cancer, KEYTRUDA plus chemoradiotherapy is now the first anti-PD-1-based regimen approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer regardless of PD-L1 expression,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.
  • The trial enrolled 1,060 patients with cervical cancer who had not previously received any definitive surgery, radiation, or systemic therapy for cervical cancer.
  • In the exploratory subgroup analysis of 596 patients with FIGO 2014 Stage III-IVA disease, 61 patients (21%) in the KEYTRUDA plus CRT arm (n=293) experienced a PFS event versus 94 patients (31%) in the placebo plus CRT arm (n=303).

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Webcast, Interest, Gynecologic Oncology Group, Therapy, ASH, Rigosertib, Protein, Breast cancer, Patient, Mantle cell lymphoma, GOG, Research, FDA, Pharmacology, Neutropenia, SCC, Diarrhea, Ovarian cancer, Cancer, Development, Internet, Society, News, Face, Pharmaceutical industry, Birth control, Video game

NEWTOWN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results and provided an update on recent pipeline progress. Management plans to host a conference call and live webcast at 4:30 p.m. ET today to discuss these results.

Key Points: 
  • ET on Tuesday, November 14, 2023
    NEWTOWN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results and provided an update on recent pipeline progress.
  • “Onconova has made excellent progress in the third quarter of 2023.
  • Research and development expenses were $2.5 million for the third quarter of 2023, compared with $3.6 million for the second quarter of 2022.
  • General and administrative expenses were $2.7 million for the third quarter of 2023, compared with $2.1 million for the second quarter of 2022.

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NDA, Paclitaxel, Woman, Institute of Cancer Research, Research, Safety, Food, Avutometinib, Cancer, Letrozole, Disease, Verastem Oncology, Patient, Anastrozole, GOG, PFS, Consultant, RAMP, Breakthrough therapy, Part, FDA, NHS foundation trust, FRAME, ORR, The Institute, Ovarian cancer, FRCP, Doctor of Philosophy, Physician, Accelerated approval (FDA), Royal Marsden Hospital, Pharmaceutical industry, MBBS, Topotecan

“Patients and treating physicians have advocated for more research and development in support of LGSOC.

Key Points: 
  • “Patients and treating physicians have advocated for more research and development in support of LGSOC.
  • At Verastem Oncology, we are moving with urgency to offer a Phase 3 study specifically directed at this disease in an effort to address this need,” said Dan Paterson, President and Chief Executive Officer, Verastem Oncology.
  • RAMP 301 is a global trial with enrollment open in the U.S. and planned enrollment in Canada, the United Kingdom, Europe, Australia, and Korea.
  • Dr. Grisham and Dr. Banerjee are paid consultants for Verastem Oncology.

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Standard of care, NSCLC, Food, Pancreas, Anastrozole, Regulatory affairs, Ovarian cancer, GAAP, Pancreatic Cancer Action Network, Paclitaxel, Accelerated approval (FDA), ORR, European Network of Transmission System Operators for Electricity, Safety, Cancer, Therapy, Investment, Patient, General Administration of Sport of China, Verastem Oncology, Topotecan, Conference, Bank statement, Clinical trial, FRAME, Travel, Letrozole, RAMP, FDA, SOC, AACR, RAS, Research and development, The Annual Global Orgasm for Peace, GOG, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, KRAS, Senior, Pharmacokinetics, European Society of Gynaecological Oncology, Lung cancer, Table, Diagnosis, Pharmaceutical industry, Bank, Finance

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.
  • Verastem Oncology ended the third quarter of 2023 with cash, cash equivalents and investments of $165.7 million.
  • Research & development expenses for the 2023 Quarter were $13.9 million, compared to $11.3 million for the 2022 Quarter.
  • Selling, general & administrative expenses for the 2023 Quarter were $7.4 million, compared to $6.4 million for the 2022 Quarter.

Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
Friday, October 20, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Bevacizumab, Neoplasm, FDA, Arm, PD-L1, Standard of care, Cervical cancer, Gynaecology, Hypothyroidism, Catholic higher education, Aes, NYSE, ESMO, Progression-free survival, Food, Trae tha Truth, Cisplatin, Congress, Chemoradiotherapy, MRK, PFS, European Society for Medical Oncology, Obstetrics, GOG, Brachytherapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, HIV disease progression rates, Creighton University School of Medicine, CPS, ClinicalTrials.gov, Merck & Co., Risk, EBRT, Immunotherapy, University, European Network for Health Technology Assessment, Woman, Safety, European Society of Gynaecological Oncology, Cancer, Patient, OS, Death, Pharmaceutical industry, Merck

Results from the trial showed that KEYTRUDA in combination with concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone for these patients.

Key Points: 
  • Results from the trial showed that KEYTRUDA in combination with concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone for these patients.
  • ET during a late-breaking abstract proffered paper session at the European Society for Medical Oncology (ESMO) Congress 2023 (abstract #LBA38).
  • After a median follow-up of 17.9 months (range, 0.9-31.0), the KEYTRUDA regimen reduced the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.55-0.89]; p=0.0020) versus concurrent chemoradiotherapy alone in these patients.
  • The 24-month PFS rate was 67.8% for patients who received the KEYTRUDA regimen compared to 57.3% for those who received concurrent chemoradiotherapy alone.

ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer

Retrieved on: 
Thursday, September 28, 2023
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Topotecan, European Society of Gynaecological Oncology, Pros, Bevacizumab, University, Progression-free survival, Neoplasm, Catholic University of Leuven (1834–1968), OS, IC, Cancer, Paclitaxel, PLD, ESGO, PFS, University Clinical Centre in Gdańsk, Mirvetuximab soravtansine, IMGN, PROC, ASCO, Congress, Ventana, American Society of Clinical Oncology, Patient, Physician, TYPE, Annual general meeting, CRS, Spacecraft, GOG, PARP, Society, ORR, Safety, Pharmaceutical industry, Medical imaging

Patients were stratified by number of prior lines of therapy (14% had one prior line of therapy, 40% had two prior lines of therapy, and 46% had three prior lines of therapy) and by IC chemotherapy, with paclitaxel as the most commonly chosen (41%), followed by PLD (36%) and topotecan (23%).

Key Points: 
  • Patients were stratified by number of prior lines of therapy (14% had one prior line of therapy, 40% had two prior lines of therapy, and 46% had three prior lines of therapy) and by IC chemotherapy, with paclitaxel as the most commonly chosen (41%), followed by PLD (36%) and topotecan (23%).
  • 62% of patients received prior bevacizumab; 55% received a prior PARP inhibitor.
  • Key secondary endpoints include objective response rate (ORR), overall survival (OS), and patient-reported outcomes (PROs).
  • ELAHERE demonstrated clinically meaningful improvements in PFS and ORR by investigator assessment and in OS compared to IC chemotherapy, regardless of prior lines of therapy (PLOT).

$2.5 million gift from The Delaney Family to create lasting impact at OCAD University

Retrieved on: 
Wednesday, September 20, 2023
University, Culture, OCAD, Galeries Ontario / Ontario Galleries, Student, Museum, Knowledge, Delaney, GOG, OCAD University, Management

Toronto, Sept. 20, 2023 (GLOBE NEWSWIRE) -- OCAD University is the recipient of a transformational gift of $2.5 million from business leader and philanthropist Kiki Delaney and The Delaney Family.

Key Points: 
  • Toronto, Sept. 20, 2023 (GLOBE NEWSWIRE) -- OCAD University is the recipient of a transformational gift of $2.5 million from business leader and philanthropist Kiki Delaney and The Delaney Family.
  • “Kiki Delaney and The Delaney Family have had such a significant impact on our institution.
  • “It is our hope that this gift will contribute to nurturing creative excellence at both Onsite Gallery and OCAD University.
  • The Delaney Family gift coincides with the announcement that Ryan Rice, Kanien’kehá:ka of Kahnawake, has been appointed Onsite Gallery’s Executive Director for a five-year term.

The International Gas Union (IGU) today releases its 2023 Global Wholesale Gas Price Survey report

Retrieved on: 
Thursday, September 21, 2023
IGU, Post-Soviet states, International Gas Union, TCP offload engine, OPE, History, Gas, COVID-19, Growth, GOG, MMBTU, Renewable energy, Natural gas, LNG

LONDON, Sept. 21, 2023 /PRNewswire/ - The International Gas Union (IGU) today releases its 2023 Global Wholesale Gas Price Survey report, the 15th undertaken since 2005.

Key Points: 
  • LONDON, Sept. 21, 2023 /PRNewswire/ - The International Gas Union (IGU) today releases its 2023 Global Wholesale Gas Price Survey report, the 15th undertaken since 2005.
  • 2021 and 2022 both saw unprecedented increases in spot prices globally with abnormal price volatility, from the depths of 2020 as Covid-19 impacted gas demand.
  • Prices have eased back somewhat in 2023, but they remain above pre-crisis levels and market conditions keep them susceptible to further volatility.
  • Gas is essential to re-establish the lost global energy security and to deliver an orderly energy transition.

The International Gas Union (IGU) today releases its 2023 Global Wholesale Gas Price Survey report

Retrieved on: 
Thursday, September 21, 2023
IGU, Post-Soviet states, International Gas Union, TCP offload engine, OPE, History, Gas, COVID-19, Growth, GOG, MMBTU, Renewable energy, Natural gas, LNG

LONDON, Sept. 21, 2023 /PRNewswire/ -- The International Gas Union (IGU) today releases its 2023 Global Wholesale Gas Price Survey report, the 15th undertaken since 2005.

Key Points: 
  • LONDON, Sept. 21, 2023 /PRNewswire/ -- The International Gas Union (IGU) today releases its 2023 Global Wholesale Gas Price Survey report, the 15th undertaken since 2005.
  • 2021 and 2022 both saw unprecedented increases in spot prices globally with abnormal price volatility, from the depths of 2020 as Covid-19 impacted gas demand.
  • Prices have eased back somewhat in 2023, but they remain above pre-crisis levels and market conditions keep them susceptible to further volatility.
  • Gas is essential to re-establish the lost global energy security and to deliver an orderly energy transition.